Paris – April 7, 2025 – HighLife SAS, a leading MedTech company focusing on the development of a novel Trans-septal Mitral Valve Replacement (“TMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its TMVR solution.